Pharsight

Qelbree is owned by Supernus Pharms.

Qelbree contains Viloxazine Hydrochloride.

Qelbree has a total of 5 drug patents out of which 0 drug patents have expired.

Qelbree was authorised for market use on 02 April, 2021.

Qelbree is available in capsule, extended release;oral dosage forms.

Qelbree can be used as for the treatment of attention deficit hyperactivity disorder (adhd), u-727: for the treatment of attention deficit hyperactivity disorder (adhd).

Drug patent challenges can be filed against Qelbree from 2025-04-02.

The generics of Qelbree are possible to be released after 07 February, 2033.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US11324753	February, 2021	Decision	Supernus Pharmaceuticals, Inc.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11324753	SUPERNUS PHARMS	Method of treatment of attention deficit/hyperactivity disorder (ADHD)	Sep, 2029 (6 years from now)
US11458143	SUPERNUS PHARMS	NA	Sep, 2029 (6 years from now)
US9603853	SUPERNUS PHARMS	Formulations of viloxazine	Feb, 2033 (9 years from now)
US9358204	SUPERNUS PHARMS	Formulations of viloxazine	Feb, 2033 (9 years from now)
US9662338	SUPERNUS PHARMS	Formulations of viloxazine	Feb, 2033 (9 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 2, 2026
New Patient Population (NPP)	Apr 29, 2025

Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient

NCE-1 date: 2025-04-02

Market Authorisation Date: 02 April, 2021

Treatment: For the treatment of attention deficit hyperactivity disorder (adhd); U-727: for the treatment of attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 100MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 150MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 200MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription